Kaitlyn D’Onofrio

DocwireNews

Different statins may shift the onset of musculoskeletal adverse events (MAEs) during statin monotherapy, researchers recently reported.&nbsp;For the study, researchers collected data from the U.S. Food &amp; Drug Administration (FDA) Adverse Event Reporting System (FAERS) Data Files. They evaluated the onset timing of musculoskeletal adverse events during statin monotherapy with seven statins:&nbsp;atorvastatin, rosuvastatin, simvastatin, lovastatin,&nbsp;fluvastatin,&nbsp;pitavastatin, and pravastatin. They also analyzed the use of concomitant drugs in conjunction with statin therapy to determine what role they played&mdash;if any&mdash;in MAE onset time.&nbsp;Researchers found the highest number of available cases for evaluation of atorvastatin monotherapy (454 cases),&nbsp;followed by rosuvastatin (413 cases), simvastatin (409 cases), pravastatin (82 cases), lovastatin (34 cases),&nbsp;fluvastatin&nbsp;(29 cases), and&nbsp;pitavastatin&nbsp;(16 cases).&nbsp;Pitavastatin&nbsp;had the shortest median time-to-onset for MAEs (14 days),&nbsp;followed by atorvastatin (24.5 days), rosuvastatin (30&nbsp;days), simvastatin (38 days), pravastatin (43 days),&nbsp;fluvastatin&nbsp;(45&nbsp;days), and lovastatin (48 days).&nbsp;Atorvastatin&nbsp;and rosuvastatin were associated not only with a high risk of MAE onset but also with a significantly faster onset of MAEs than simvastatin. There were not enough available data to compare onset time of MAEs in other statins.&nbsp;There were data available on 24 different individual drugs used concurrently with atorvastatin in at least 30 cases, and the most common drug was aspirin. Compared to atorvastatin alone,&nbsp;lisinopril&nbsp;was associated with the shortest time-to-onset of MAEs (3 days), and&nbsp;losartan&nbsp;was associated with the longest time-to-onset of MAEs (74 days). The difference was not statistically significant when comparing time-to-onset of MAEs between atorvastatin monotherapy and atorvastatin with the 24 concomitant drugs.&nbsp;The study had several limitations, including that it&nbsp;did not include data from prior to 2004. Therefore, data from a study conducted in 2004, which focused on statin use prior to 2001, were not included in this analysis. The present study also only considered four MAEs: rhabdomyolysis, myoglobinuria, myalgia, and blood creatine phosphokinase increased. Finally, researchers could not evaluate changes in onset timing of MAEs attributable to statin dosage.&nbsp;&ldquo;Statins with strong low&#8208;density lipoprotein cholesterol&#8208;lowering effects (atorvastatin and rosuvastatin) contributed not only to a high risk of MAE onset, but also to a shorter time&#8208;to&#8208;onset. No concomitant drug significantly shifted the onset timing of MAEs when used concurrently with statins,&rdquo; the study authors concluded.&nbsp;<a href="https://proddocwire.wpengine.com/cardiology/long-term-statin-remains-safe/">Report: Long-term Statin Use Remains Safe, With Low Risk for Adverse Events</a>&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/cardiac-allograft-valvuloplasty/">Early Statin Use Yields Attenuated CAV Progression, Risk Reduction</a>&nbsp;<a href="https://proddocwire.wpengine.com/abstracts/low-density-lipoprotein-cholesterol/">High-Intensity Versus Non-High-Intensity Statins in Patients Achieving Low-Density Lipoprotein Cholesterol Goal After Percutaneous Coronary Intervention</a>&nbsp;<a href="https://proddocwire.wpengine.com/cardiology/perceptions-of-cardiovascular-risk-and-beliefs-on-statin-drugs-with-racial-differences-in-statin-use/">Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs with Racial Differences in Statin Use</a>Source:&nbsp;<a href="https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1002/prp2.439">British Pharmacological Society</a>

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Analysis: Statins and their Association with Musculoskeletal Adverse Event Onset Time

Rheumatology

Different statins may shift the onset of musculoskeletal adverse events (MAEs) during statin monotherapy, researchers recently reported.  ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe